D-1112-2018 Class III Terminated

Recalled by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) — Rockford, IL

FDA drug recall D-1112-2018 was initiated by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) on Aug 14, 2018 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications; out of specification results for related compound per the manufacturer The recall status is terminated (terminated Jun 26, 2020). Affected quantity: 408 cartons.

Recall details

Product Type
Drugs
Report Date
Aug 29, 2018
Initiation Date
Aug 14, 2018
Termination Date
Jun 26, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
408 cartons

Product description

Diltiazem HCl Extended-release Capsules, USP 120 mg, 80 capsules, 8 blister cards of 10 capsules each per carton, Rx Only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV. NDC 51079-947-08

Reason for recall

Failed Impurities/Degradation Specifications; out of specification results for related compound per the manufacturer

Distribution pattern

Nationwide USA

Code information

Batch 3096049

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1112-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1112-2018. Report a data issue: hello@regdatalab.com.